

Male Hypogonadism Market Explore Growth Factors, Competitive Analysis of Key Industry Players

Male Hypogonadism Market is estimated to reach \$3,233 million by 2022, growing at a CAGR of 3.1% from 2016 to 2022.

PORTLAND, OREGON, UNITED STATES, January 20, 2022
/EINPresswire.com/ -- Male hypogonadism is a clinical condition in which testes cannot produce enough testosterone, resulting in decreased



development of muscle mass, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.

Growth in the male hypogonadism market is driven by the rise in prevalence & incidence of men with testosterone deficiency, increase in infertility rates, and growth in awareness among the patient population about hypogonadism treatment options by certain campaigns carried out by the government. Moreover, the risk of hypogonadism is very high in the geriatric population, and population with obesity & diabetes; thus, growth in geriatric population and incidence of chronic lifestyle disorders, such obesity & diabetes, are further expected to boost the market growth.

However, high side effects of all testosterone products are expected to hinder growth of the testosterone replacement therapy (TRT) segment in this market. Technological advancements are expected to provide new opportunities during the forecast period.

0000000 000000 000000 https://www.alliedmarketresearch.com/request-sample/1874

Key players have adopted product approval as their key strategy to cater to the changing needs of the industry. There is high competition among key players to launch innovative, technologically advanced products to increase their market share and serve the patients in a better way. Major players operating in this market include AbbVie Inc., Allergan plc, AstraZeneca plc, Bayer AG, Eli Lilly and Company Ltd., Endo International plc, Merck & Co., Inc., Ferring Holding S.A., Finox Biotech, IBSA Institut Biochimque SA, Laboratoires Genevrier, and Teva Pharmaceutical Industries Ltd.

- •By drug therapy, gonadotropin and gonadotropin-releasing hormones therapy segment is projected to grow at the highest CAGR of 8.9% during the forecast period.
- •Bituitary disorders segment is expected to grow at the CAGR of 3.2%.
- •Injectables accounted for nearly half of the market share in 2015.
- •North America accounted for majority of the share (more than three-fourths) in 2015, and is expected to remain dominant throughout the forecast period.
- D.S. accounted for the majority share in the North American market in 2015, and the Mexican market is expected to grow at the highest CAGR of 6.7%.

000 000000 000000 https://www.alliedmarketresearch.com/male-hypogonadism-market

0000000 0000000:

Vascular Graft Market

Hospital-Acquired Infection Diagnostics Market

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive

& Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/561055838

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2022 IPD Group, Inc. All Right Reserved.